Chemotherapy-induced peripheral neuropathy: part 1—current state of knowledge and perspectives for pharmacotherapy

Background Despite the increasing knowledge of the etiology of neuropathic pain, this type of chronic pain is resistant to available analgesics in approximately 50% of patients and therefore is continuously a subject of considerable interest for physiologists, neurologists, medicinal chemists, pharm...

Full description

Saved in:
Bibliographic Details
Published inPharmacological reports Vol. 72; no. 3; pp. 486 - 507
Main Author Sałat, Kinga
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.06.2020
Subjects
Antineoplastic Agents - adverse effects
Cisplatin - adverse effects
Drug Safety and Pharmacovigilance
Humans
Medicine
Neuralgia - chemically induced
Neuralgia - epidemiology
Neuralgia - physiopathology
Oxaliplatin - adverse effects
Pharmacotherapy
Pharmacy
Review
Platinum derivatives
Bortezomib
Vinca alkaloids
Chemotherapy-induced peripheral neuropathy
Neuronal hyperexcitability
Paclitaxel
Online AccessGet full text

Cover

More Information
Summary:Background Despite the increasing knowledge of the etiology of neuropathic pain, this type of chronic pain is resistant to available analgesics in approximately 50% of patients and therefore is continuously a subject of considerable interest for physiologists, neurologists, medicinal chemists, pharmacologists and others searching for more effective treatment options for this debilitating condition. Materials and methods The present review article is the first of the two articles focused on chemotherapy-induced peripheral neuropathy (CIPN). Results CIPN is regarded as one of the most common drug-induced neuropathies and is highly pharmacoresistant. The lack of efficacious pharmacological methods for treating CIPN and preventing its development makes CIPN-related neuropathic pain a serious therapeutic gap in current medicine and pharmacotherapy. In this paper, the most recent advances in the field of studies on CIPN caused by platinum compounds (namely oxaliplatin and cisplatin), taxanes, vinca alkaloids and bortezomib are summarized. Conclusions The prevalence of CIPN, potential causes, risk factors, symptoms and molecular mechanisms underlying this pharmacoresistant condition are discussed. Graphic abstract
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1734-1140
2299-5684
2299-5684
DOI:10.1007/s43440-020-00109-y